Zai Lab (09688.HK) (ZLAB.US) announced that the biologics application for Egatolimod subcutaneous injection, a product developed in collaboration with Argenx (ARGX.US), has been approved by the National Medical Products Administration for the treatment of adult generalized myasthenia gravis (gMG) patients who are acetylcholine receptor (AChR) antibody-positive and who are being treated with conventional drugs.

Rafael G. Amado, CEO and Head of Global R&D at Zai Lab, expressed his delight that the National Medical Products Administration has approved the marketing application for Egatolimod, which will provide another treatment option for gMG patients in China. In addition to increasing the flexibility of treatment, it is also expected to further simplify the treatment plan and improve the accessibility of treatment.

The company also noted that the potential therapeutic application of Egatolimod subcutaneous injection in other autoimmune diseases is currently under exploration.